Time points | T1 | T2 | T3 | T4 | T5 | T6 | T7 |
---|---|---|---|---|---|---|---|
Sample size | 116 | 145 | 105 | 95 | 91 | 107 | 137 |
Clinic population size | 220 | 245 | 285 | 286 | 315 | 336 | 355 |
Men | 45 (39%) | 63 (43%) | 45 (43%) | 39 (41%) | 33 (36%) | 51 (48%) | 61 (44%) |
Women | 71 (61%) | 82 (57%) | 60 (57%) | 56 (59%) | 58 (64%) | 56 (52%) | 76 (56%) |
Age, mean (SD) [Range] | 25.1 (6.7) [16–50] | 24.7 (7.3) [14–51] | 26.3 (7.8) [14–53] | 28.6 (7.3) [16–51] | 29.7 (8.1) [18–50] | 31.6 (7.5) [20–55] | 33.7 (7.8) [22–57] |
FEV1%, mean (SD) [Range] | 58.5% (24.4) [14.0–133.0%] | 59.6% (23.9) [12.0–128.0%] | 60.8% (24.4) [16.0–128.0%] | 59.6% (22.9) [20.0–113.0%] | 57.0% (24.8) [16.0–109.0%] | 57.3% (23.9) [14.0–119.0%] | 56.9% (23.3) [14.0–114.0%] |
Mild disease, N (%) | 41 (35%) | 55 (38%) | 40 (38%) | 30 (32%) | 30 (33%) | 32 (30%) | 38 (28%) |
Moderate disease, N (%) | 42 (36%) | 58 (40%) | 39 (37%) | 44 (46%) | 32 (35%) | 46 (43%) | 63 (46%) |
Severe disease, N (%) | 33 (29%) | 32 (22%) | 26 (25%) | 21 (22%) | 29 (32%) | 29 (27%) | 36 (26%) |
BMI, mean (SD) [Range] | 21.4 (3.1) [15.6–30.2] | 21.5 (2.9) [16.0–30.1] | 21.9 (3.1) [15.1–33.1] | 22.0 (2.7) [16.3–29.2] | 22.0 (3.2) [13.3–33.7] | 21.9 (3.2) [16.8–34.2] | 21.3 (3.2) [16.1–33.8] |
IV access device | 47 (41%) | 72 (50%) | 50 (48%) | 46 (48%) | 51 (56%) | 66 (62%) | 85 (62%) |
B cepacia complex | 7 (6%) | 13 (9%) | 10 (10%) | 10 (11%) | 4 (4%) | 10 (9%) | 8 (6%) |
CF-related diabetes | 26 (22%) | 49 (34%) | 38 (36%) | 32 (34%) | 36 (40%) | 49 (46%) | 69 (50%) |
Oral nutritional supplements | 44 (38%) | 45 (31%) | 36 (34%) | 25 (26%) | 30 (33%) | 37 (35%) | 44 (32%) |
Enteral tube feeds | 24 (21%) | 27 (19%) | 10 (10%) | 16 (17%) | 9 (10%) | 16 (15%) | 26 (19%) |
Post-transplant | 11 (9%) | 14 (10%) | 12 (11%) | 17 (18%) | 14 (15%) | 13 (12%) | 18 (13%) |
BMI, body mass index; CF, cystic fibrosis; FEV1%, forced expiratory volume in 1 s; IV, intravenous.